Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥64.00
¥1.00(1.52%)
At close: 4:00 PM EDT
¥64.00
¥1.00(1.52%)
Day’s Range― - ―
52-Week Range¥44.00 - ¥229.00
Previous CloseN/A
Volume398.00K
Average Volume (3M)529.19K
Market Cap
¥3.72B
Enterprise Value¥5.25B
Total Cash (Recent Filing)¥977.18M
Total Debt (Recent Filing)¥832.50M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Feb 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.06
Shares Outstanding84,548,960
10 Day Avg. Volume718,600
30 Day Avg. Volume529,190
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe retained high gross margin indicates the company can generate substantial value after direct production costs. If operating expenses are brought into line, this underlying economics could support profitability, although current losses show the benefit is not yet realized.
Specialized Oncology FocusA focused oncology and hematology strategy gives the company a defined therapeutic scope, while external manufacturing and licensing partnerships provide an established route to regulatory progress and commercialization. This model can support indication expansion and market access.
Meaningful Asset BaseA meaningful asset base provides the company with resources supporting continued pharmaceutical development and commercialization activities. Although leverage and equity erosion reduce flexibility, this asset foundation remains a constructive feature for sustaining operations over the medium term.
Bears Say
Sustained Revenue DeclineRepeated revenue contraction signals weakening commercial momentum rather than a single-period fluctuation. Continued top-line pressure can reduce the scale available to absorb research, selling, and administrative costs, making a return to sustainable profitability more difficult.
Deepening LossesThe multi-year deterioration in operating and net profitability indicates that high gross margin is being overwhelmed by costs outside direct production. Persistent losses erode retained equity and limit the company’s ability to reinvest, fund development, or withstand execution setbacks.
Negative Cash GenerationThe business is not currently funding itself from operations, and the recent acceleration in cash burn raises reliance on external financing. If losses and outflows persist, liquidity pressure could constrain development plans and reduce management’s strategic flexibility.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥44.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥3.72B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Feb 11, 2027 which is in 103 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Oct 29, 2026. The company reported -¥15.006 earnings per share for the quarter.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 84,548,960 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥15.006 in its last earnings report. Following the earnings report the stock price went down -2.128%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―